Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 4/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.42 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | WHR1 | P49842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20620894 | 1.00 | NSD2 (0.53) | NSD2EHMT2TLR9KDM1ARCOR1 | |
| SCHEMBL22026561 | 0.88 | KMT5A (0.55) | NSD2EHMT2TLR9DNMT3AKMT5A | |
| SCHEMBL20620895 | 0.86 | NSD2 (0.54) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL20620893 | 0.86 | NSD2 (0.54) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL29453059 | 0.82 | KMT5A (0.62) | NSD2EHMT2KMT5AWHR1 | |
| SCHEMBL20621265 | 0.82 | KMT5A (0.62) | NSD2EHMT2KMT5AWHR1 | |
| SCHEMBL3920538 | 0.78 | PDE4A (0.48) | NSD2EHMT2PIK3CDPIM1PIM2 | |
| SCHEMBL12390464 | 0.78 | NSD2 (0.70) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL22026549 | 0.76 | EHMT2 (0.58) | EHMT2DNMT3AWHR1 | |
| SCHEMBL22026551 | 0.76 | EHMT2 (0.58) | EHMT2DNMT3AWHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254654-B2 | Heterochromatin gene repression inhibitors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200181116-A1 | HETEROCHROMATIN GENE REPRESSION INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-11 | — | — | US | disclosed |
| WO-2019006322-A1 | HETEROCHROMATIN GENE REPRESSION INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254654-B2 | Heterochromatin gene repression inhibitors | CTCF, EHMT2, CBX3 | NSD2 163/4885EHMT2 2/4885TLR9 4800/4885 |
| US-20200181116-A1 | HETEROCHROMATIN GENE REPRESSION INHIBITORS | CTCF, EHMT2, CBX3 | NSD2 163/4885EHMT2 2/4885TLR9 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.